Actively Recruiting
Study to Evaluate Two Doses of Quizartinib as Maintenance Therapy in Adults with FLT3-ITD Positive Acute Myeloid Leukemia in First Remission
Led by Daiichi Sankyo · Updated on 2026-09-16
130
Participants Needed
64
Research Sites
214 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying two different doses of quizartinib as maintenance treatment in adults with FLT3-ITD positive acute myeloid leukemia AML who are in their first complete remission and have not undergone allogeneic hematopoietic stem cell transplantation. This phase 2 trial aims to evaluate the safety and effectiveness of these doses in preventing relapse and improving survival. Participants are randomly assigned to receive either a higher or lower daily oral dose of quizartinib. The study also includes a sub-study using Holter monitoring to assess the impact of rapid heart rate changes on the drugs cardiac safety. Treatment continues for up to 87 months or until disease progression or other criteria are met. Throughout the trial, participants undergo regular assessments including monitoring for serious and general treatment-emergent adverse events, overall survival, and relapse-free survival. Heart function and safety are closely observed, particularly through Holter monitoring. The study lasts several years, with follow-up continuing up to 87 months after starting treatment to ensure comprehensive safety and efficacy data collection.
CONDITIONS
Brief Title
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
Research Team
C
Contact for Trial Information
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here